HARMOCELL
Product identity, market education and international partner coordination.
PRODUCT · PROCESS · PROOF
A sublingual tablet.
Powered by EV science.
HARMOCELL Black Gold is a non-drug, rapidly dispersing wellness tablet that brings an extracellular-vesicle platform, freeze-drying protection and finished-lot quality controls into one convenient format.
LOT HK202607-BGEV COUNT 11.4 × 10⁹ / tabletPEAK SIZE 119.3 nmFORMAT 2.1 sec sublingual release
WHO STANDS BEHIND THE PRODUCT
Four roles. Clearly defined.
The brand, technology developer, hospital research collaborator and finished-product manufacturer are separate organizations with different responsibilities.
Hexie Technology Co., Ltd.
Applicant or patentee across the supplied stem-cell and extracellular-vesicle patent portfolio.
Peking Union Medical College Hospital
Joint applicant with Beijing Xiehe Technology on CN119464200A through the Chinese Academy of Medical Sciences.
Hubei Feirui Biopharmaceutical Co., Ltd. (Hebei)
Manufacturer named in the supplied finished-product quality specification for lot HK202607-BG.
01 / WHAT THE PRODUCT IS
BLACK GOLD SERIES
A tablet format for a
complex biological platform.
The Black Gold Series translates advanced extracellular-vesicle research into a precisely portioned sublingual format—without injections, living cells or a complicated daily procedure.
PRODUCT CATEGORYSublingual flash-release tablet
POSITIONINGNon-drug cellular wellness
LOT TESTEDHK202607-BG
SHELF LIFE24 months
Designed for wellness positioning. Not intended to diagnose, treat, cure or prevent disease.
EV-based sublingual tablet
A precisely portioned, non-injectable tablet designed to disperse beneath the tongue.
Controlled biological process
Cell platform, EV isolation, characterization, lyoprotection, tablet forming and protected packaging.
Protecting nano-scale structures
Particle integrity, contamination control, batch consistency and rapid disintegration must be balanced in one finished format.
Finished-lot specification
NTA particle analysis, EV-marker checks, disintegration, sterility, endotoxin and heavy-metal controls.
02 / BATCH EVIDENCE
FINISHED-PRODUCT TESTING
Not a concept.
A measured lot.
These values are reported in the Finished Product Quality Specification Statement for lot HK202607-BG, tested 28 July 2026. The document is available below for partner review.
EV particles / tablet
NTA lot result
PASSPeak particle size
80–140 nm specification
PASSMain peak ratio
≥90% specification
PASSSublingual disintegration
<3.0 sec specification
PASSCD9Positive (+)EV marker · Western blot
CD63Positive (+)EV marker · Western blot
CalnexinNegative (−)Non-EV marker · cell-free
SafetySterile / heavy metals undetectedEndotoxin <0.05 EU/mL
VERIFICATION DOCUMENTFinished Product Quality Specification
Open PDF ↗Lot HK202607-BG · Spec Doc HK202607-BG-QS
03 / EXPERIENCE & COMMERCIAL OUTLOOK
WHAT THE FORMAT OFFERS
Simple to understand.
Distinctive to present.
The immediate product benefit is format-led: portable single-tablet dosing, rapid sublingual dispersion and no injection procedure. Biological efficacy must be evaluated separately and should not be inferred from format or patent ownership.
Fast, convenient daily use
The tested lot reports 2.1-second disintegration under the stated specification.
Premium cellular-wellness category
A differentiated story for wellness, clinic and distributor channels supported by product, factory, quality and patent materials.
Platform potential
The broader patent portfolio covers EV extraction, compositions, culture systems and lyophilization—creating a foundation for future formats subject to validation and local regulation.
Evidence boundaryUser testimonials are anecdotal and are not presented as clinical proof. No claim is made that this product diagnoses, treats, cures or prevents disease.
04 / TECHNICAL CHALLENGES
ONE CONNECTED DEVELOPMENT PATH
From cell culture to a
stable sublingual format.
HARMOCELL’s differentiation is not one isolated ingredient. It is the integration of extraction, characterization, stabilization and delivery into a connected technology pathway.
Cellular platform
Research into mesenchymal-stem-cell culture and extracellular-vesicle production.
Patent family foundationEV extraction
Staged separation, filtration and ultracentrifugation designed to isolate nano-scale vesicles.
CN114591901B · grantedCharacterization
NTA particle sizing and Western blot marker checks distinguish the finished lot.
119.3 nm · CD9+/CD63+Lyoprotection
Protectant systems and multi-step freeze-drying address structural damage during stabilization.
0.95–0.99 relative SIRT6 expression in patent examplesFlash release
A sublingual dispersible format engineered for convenience and rapid tablet disintegration.
2.1 seconds · finished lotPatent example data describe the patented technology and are not clinical efficacy claims for the finished consumer product.
05 / MANUFACTURING & PROCESS
MANUFACTURING RESPONSIBILITY
One named manufacturer.
One documented lot.
The supplied specification identifies Hubei Feirui Biopharmaceutical Co., Ltd. (Hebei) as the finished-product manufacturer for lot HK202607-BG. The production overview below explains the represented workflow.
MANUFACTURERHubei Feirui Biopharmaceutical Co., Ltd. (Hebei)
FINISHED LOTHK202607-BG
QUALITY FRAMEWORK STATED IN SOURCEISO 22000:2018 · SC11313097100236
Open manufacturer quality statement ↗Qualified inputs→Controlled formulation→Flash-release forming→Blister protection→Lot release
06 / INTELLECTUAL PROPERTY
PROTECTED DEVELOPMENT
Patents you can
open and examine.
Rather than treating “patented” as a slogan, we show the publication number, legal stage, named inventors and original document for partner diligence.
Granted · 2023CN114591901B
Extracellular vesicle extraction
A granted method patent covering culture conditions, staged purification and extraction from umbilical cord mesenchymal stem cells.
Inventors: Guihua Yang, Haixia Yang, Jinjun ZhaoPublished · 2025CN119464200A
SIRT6 EV lyophilization protection
A multi-component lyoprotectant and controlled freeze-drying process designed to preserve extracellular-vesicle structure and biological functionality.
Inventors: Zhihong Wu, Guihua Yang, Su Liu, Jinjun ZhaoUnder examinationCN120478292A
Sublingual dispersible tablet protection
A lyophilized protectant, preparation method and application for sublingual dispersible tablets containing stem-cell extract.
Inventors: Liu Baohua, Yang Huahua, Zhao JinlianView broader cellular biotechnology portfolio +
07 / PEOPLE & TRACEABLE EVIDENCE
PEOPLE BEHIND THE RECORDS
Named inventors.
Visible evidence.
Inventor status is shown only where a supplied patent document names the person. Other contributors are presented through their documented clinical, quality, research or production roles.
01 Named in patent record02 Patent source opens directly03 Non-inventors shown by documented role
Patent-linked inventors
Chief Scientist · Named Inventor
Professor Baohua Liu, PhD
Aging-biology specialist and named inventor on a sublingual dispersible-tablet lyophilization and protection technology application.
Founder · Named Inventor
Jinjun Zhao, PhD
Named across five supplied patent publications covering stem-cell preparation, EV extraction, formulation, culture media and SIRT6 EV lyophilization.
Head of Stem Cell Research · Named Inventor
Haixia Yang, PhD
Co-inventor of supplied records covering mesenchymal-stem-cell exosome extraction and an exosome-based composition platform.
Clinical, quality & translation contributors
Documented expertise—not presented as patent inventorship.
R&D leadership · Bioengineering
Rui Yang, PhD
Biomedical-engineering training and multidisciplinary product/process development.
ROLE-BASED EVIDENCE
Production · Process transfer
Feng Li, PhD
Research-to-production transfer, controlled manufacturing and process scale-up.
ROLE-BASED EVIDENCE
Medical evaluation · Clinical translation
Professor Hongqiang Feng
Chief-physician and doctoral-supervision background supporting medical review and translational guidance.
ROLE-BASED EVIDENCE
Academic research adviser
Professor Di Chen
Academic direction in cell biology and interdisciplinary research strategy.
ROLE-BASED EVIDENCE
Quality and cell-resource adviser
Professor Baozhu Yuan
Stem-cell expert committee and cell-resource quality experience reported in the supplied company profile.
ROLE-BASED EVIDENCE
Clinical and translational research adviser
Professor Yunfang Wang
Medical research and clinical-translation leadership reported in the supplied company profile.
ROLE-BASED EVIDENCE
Biomaterials adviser
Professor Haobo Pan
Biomaterials and interdisciplinary biomedical-research expertise.
ROLE-BASED EVIDENCEProfiles summarize the credentials, affiliations and project roles documented in supplied company materials.
PARTNER DILIGENCE
See the product.
Review the evidence.
Then start the conversation.
Technical dossiers, patent documents and batch information are available for qualified distribution, clinic and brand partners.
Request partnership information ↗young910830@gmali.com